Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Neuropsychological treatment, Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU)., Waitlist group.
- Кому может быть актуально
- Состояния в реестре: Cancer, Breast. Базовые параметры: 18 лет — 70 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Испания
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Effectiveness of Cognitive Rehabilitation and the Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments: a Randomized Controlled Trial
Обзор
Background: Cognitive impairment appears frequently in cancer survivors, negatively affecting the quality of life and emotional well-being of patients. This study compares the effectiveness of a well-established treatment (cognitive rehabilitation) with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to alleviate these cognitive deficits and evaluate its effect on anxiety-depressive symptoms and the quality of life of survivors. Methods: A three-arm randomized superiority clinical trial, with a pre-post and follow-up repeated measures and intergroup design with a 1:1:1 allocation ratio will be carried out. A hundred and twenty-three breast cancer survivors with mild to moderate cognitive impairment will be randomly assigned to one of the interventions of the study: cognitive rehabilitation intervention group, an intervention group with UP intervention, or a control group on the waiting list. The primary outcome is to observe a significant improvement in cognitive function and quality of life in both intervention groups and a significant decrease in emotional impairments in comparison with the waitlist group. These results will be maintained at six months of follow-up. Discussion: The aim of this work is to test the efficacy of the Unified Barlow Protocol in reducing cognitive deficits in breast cancer survivors. The results of this trial may be useful in reducing the presence of cognitive problems in survivors and improving their emotional state and quality of life.
Вмешательства
- Поведенческое Neuropsychological treatment
combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying diffi - Поведенческое Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).
This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used ( - Поведенческое Waitlist group
The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
Первичные конечные точки
- Functional assessment of Cancer Therapy-Cognitive Function, version 3. (FACT-Cog). [Срок оценки: Change of mean scores from baseline to immediately after intervention]
- Memory Failures Everyday (MFE-30). [Срок оценки: Change of mean scores from baseline to immediately after intervention]
- Hopkins Verbal Learning Test-Revised (HVLT-R). [Срок оценки: Change of mean scores from baseline to immediately after intervention]
- Trail Making Test (TMT). [Срок оценки: Change of mean scores from baseline to immediately after intervention]
- Controlled Oral Word Association Test (COWAT). [Срок оценки: Change of mean scores from baseline to immediately after intervention]
Вторичные конечные точки (2)
- Hospital Anxiety and Depression Scale (HADS) [Срок оценки: Change of mean scores from baseline to immediately after intervention]]
- Quality of Life scores using EORTC QLQ C-30. [Срок оценки: Change of mean scores from baseline to immediately after intervention]]
Критерии участия
Критерии включения
- Cancer diagnosis, stages I-III.
- Cancer type: Breast.
- Have received the last chemotherapy session in the last 6 months and a maximum of 6 years of treatment completion.
- Probable or mild to moderate cognitive impairment (score between 26 and 10 points according to the MMSE).
- Ability to be fluent in Spanish.
- Not currently participating in another clinical trial.
- Not currently receiving other psychological treatment
Критерии исключения
- Men and women aged > 70 years.
- Diagnosis of cancer, stage IV or other types of cancer.
- Last chemotherapy session < 6 months or > 6 years.
- No cognitive impairment (MMSE score between 30 and 27 points).
- Diagnosis of mental disorder (including substance abuse) prior to cancer diagnosis.
- Relapse in disease after chemotherapy treatment is completed.
- Neurodevelopmental Disorder Diagnosis.
- Diagnosis of diseases that affect cognitive performance such as: hypertension, cardiac diseases, epilepsy, dementias, multiple sclerosis, functional disorders (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, post-concussion syndrome, whiplash syndrome), CNS infections (HIV, encephalitis), metabolic disorders (diabetes, B12 deficiency), obstructive sleep apnea, brain damage (stroke, TBI, CNS cancer) and use of medications / substances that interfere with cognitive function such as pregabalin, gabapentin, topiramate, antidepressants tricyclics, sodium valproate, anticholinergics, methylphenidate, typical antipsychotics.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Тройное слепое
- Основная цель
- Лечение
Центры проведения
Испания · 2 центра
- Hospital Universitario Reina Sofía — Córdoba
- Reina Sofía University Hospital — Córdoba
Публикации
- Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trial. Trials. 2022 Sep 30;23(1):819. doi: 10.1186/s13063-022- PMID 36175973
Идентификаторы
NCT: NCT05289258 · 1380800-R